Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis – A retrospective study (FUTURE)

Authors




Prof. Dr. Kristian Reich
DERMATOLOGIKUM HAMBURG
Stephansplatz 5
D-20354 Hamburg, Germany
Tel.: +49-40-351075-79
Fax: +49-40-351075-40
E-mail: reich@dermatologikum.de

Summary

Background: This study collected data on the safety and efficacy of fumaric acid esters (FAE; Fumaderm®) in the long-term treatment of psoriasis.

Patients and Methods: Patients were included at 163 dermatological centers if they either had been treated continuously with FAE for at least 24 months, or for 36 months with interruptions of no longer than 6 months. Data were reported from baseline, after 3, 6, 12, 24, and 36 or more months of therapy. Safety parameters were monitored and the severity of skin symptoms was assessed by “Physician's Global Assessment” (PGA) and “Psoriasis Area and Severity Index” (PASI).

Results: 984 patients were included with a mean duration of 44 months of continuous treatment. The percentage of patients documented as markedly improved or clear was 67 % after six months, 78 % after 24 months, and 82 % after 36 months of therapy. Improvement was similar in patients with moderate and severe disease. Changes of laboratory parameters were usually insignificant and did not require a modification of FAE treatment in more than 90 % of the cases.

Conclusions: In the long-term treatment of patients with moderate and severe psoriasis FAE show a good and sustained clinical efficacy combined with a favorable safety profile.

Ancillary